{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:50:53Z","timestamp":1786996253662,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.revmed.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:44:52Z","timestamp":1747755892000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint inhibitor-related eosinophilic fasciitis: 3\u00a0case reports with literature review"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9557-2927","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Biteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-5804","authenticated-orcid":false,"given":"Alexandre","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuelle","family":"Uro-Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Pastissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cougoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Delavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tthibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6202-8496","authenticated-orcid":false,"given":"Val\u00e9rian","family":"Rivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.05.004_bib0195","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.revmed.2025.05.004_bib0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.05.004_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jamiaopen\/ooy045","article-title":"Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis","volume":"2","author":"Wang","year":"2019","journal-title":"JAMIA Open"},{"key":"10.1016\/j.revmed.2025.05.004_bib0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.revmed.2019.09.005","article-title":"Toxicit\u00e9s immunologiques induites par les inhibiteurs de checkpoint en 2019\u00a0: mise au point","volume":"41","author":"Comont","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2025.05.004_bib0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/ph16020259","article-title":"Checkpoint inhibitor-associated scleroderma and scleroderma mimics","volume":"16","author":"Macklin","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.revmed.2025.05.004_bib0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.14160","article-title":"Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis","volume":"45","author":"Jinnin","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2025.05.004_bib0230","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaad.2021.05.030","article-title":"Drug-induced eosinophilic fasciitis: a dual pharmacovigilance analysis","volume":"86","author":"Teboul","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0235","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/ijms24031982","article-title":"Eosinophilic fasciitis: current and remaining challenges","volume":"24","author":"Mazilu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2025.05.004_bib0240","doi-asserted-by":"crossref","first-page":"rkaa001","DOI":"10.1093\/rap\/rkaa001","article-title":"Nivolumab-induced eosinophilic fasciitis: a case report","volume":"4","author":"Ollier","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.revmed.2025.05.004_bib0245","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jtho.2018.09.016","article-title":"An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab","volume":"14","author":"Le Tallec","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0250","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223249","article-title":"Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab","author":"Parker","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0255","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1078560","article-title":"Case report: eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET\/CT","volume":"9","author":"Amrane","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.revmed.2025.05.004_bib0260","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/rheumatology\/kez164","article-title":"Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response","volume":"58","author":"Toussaint","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2025.05.004_bib0265","article-title":"Complete reversibility of pembrolizumab-induced eosinophilic fasciitis without corticosteroids: a case report","volume":"9","author":"Bourcier","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0270","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.932888","article-title":"Drug-associated eosinophilic fasciitis: a case of eosinophilic fasciitis secondary to cemiplimab therapy","volume":"22","author":"Boppana","year":"2021","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.revmed.2025.05.004_bib0280","doi-asserted-by":"crossref","first-page":"376","DOI":"10.31138\/mjr.32.4.376","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy with pembrolizumab","volume":"32","author":"Zampeli","year":"2021","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0285","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.revmed.2025.05.004_bib0290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/JIPO.JIPO_8_19","article-title":"Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer","volume":"2","author":"Wissam","year":"2019","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0295","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jdcr.2020.04.017","article-title":"Eosinophilic fasciitis in association with nivolumab: the importance of eosinophilia","volume":"6","author":"Pab\u00f3n-Cartagena","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0300","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jdcr.2020.04.010","article-title":"Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression","volume":"6","author":"Bui","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0305","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jtho.2019.09.011","article-title":"Eosinophilic fasciitis triggered by nivolumab: a remarkable efficacy of the mTOR inhibitor sirolimus","volume":"15","author":"Le Tallec","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.36401\/JIPO-21-19","article-title":"Eosinophilic fasciitis with concurrent necrobiotic granulomatous dermatitis related to checkpoint inhibition therapy","volume":"5","author":"Haroon","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0315","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40744-020-00246-z","article-title":"Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a pembrolizumab-induced \u201ceosinophilic fasciitis-like\u201d case and a review of the literature","volume":"7","author":"Salamaliki","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.revmed.2025.05.004_bib0320","first-page":"182","article-title":"Immune checkpoint inhibitor-induced eosinophilic fasciitis: a case report and literature review","volume":"62","author":"Ouyang","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.revmed.2025.05.004_bib0325","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/rheumatology\/kex369","article-title":"Immune checkpoint inhibitor-induced myo-fasciitis","volume":"56","author":"Daoussis","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2025.05.004_bib0330","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.annder.2023.07.001","article-title":"Nivolumab-induced eosinophilic fasciitis: an unusual immune-related adverse event that needs to be recognized by practitioners","volume":"150","author":"Benzaquen","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0335","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1684\/ejd.2021.4181","article-title":"Nivolumab-induced multiple morphea associated with eosinophilic fasciitis","volume":"31","author":"Lacombe","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0340","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2025.05.004_bib0345","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2020.11.019","article-title":"Skin puckering and edema during durvalumab therapy","volume":"7","author":"Olamiju","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2025.05.004_bib0350","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.revmed.2025.05.004_bib0355","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.berh.2012.08.001","article-title":"Eosinophilic fasciitis (Shulman disease)","volume":"26","author":"Lebeaux","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0360","first-page":"e31140","article-title":"An unusual presentation of a rare disease: eosinophilic fasciitis","volume":"14","author":"Dakhode","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.revmed.2025.05.004_bib0365","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaad.2022.08.026","article-title":"Cluster analysis reveals eosinophilia and fibrosis as poor prognostic markers in 128 patients with eosinophilic fasciitis","volume":"87","author":"Chaigne","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0370","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jaad.2023.08.063","article-title":"Utility of magnetic resonance imaging in the diagnosis of eosinophilic fasciitis: a multicenter retrospective cohort study","volume":"89","author":"Shahriari","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2025.05.004_bib0375","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/ijms24031982","article-title":"Eosinophilic fasciitis: current and remaining challenges","volume":"24","author":"Mazilu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2025.05.004_bib0380","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","article-title":"Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases","volume":"17","author":"Lakhanpal","year":"1988","journal-title":"Semin Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T12:36:04Z","timestamp":1751200564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325006149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0248866325006149"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.05.004","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related eosinophilic fasciitis: 3\u00a0case reports with literature review","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}